Journal
JOURNAL OF THROMBOSIS AND THROMBOLYSIS
Volume 51, Issue 1, Pages 151-158Publisher
SPRINGER
DOI: 10.1007/s11239-020-02154-z
Keywords
Prothrombin complex concentrates; Intracranial hemorrhages; Hematomas; Factor xa inhibitors; Direct oral anticoagulants; Hemostatics
Ask authors/readers for more resources
In patients with ICH taking apixaban or rivaroxaban, both aPCC and 4F-PCC demonstrate effective hemostasis with no significant differences in safety outcomes, suggesting they are equally viable options for managing hemorrhage in these patients. Prospective studies are needed to determine the optimal reversal agent and dosing strategy for ICH associated with apixaban or rivaroxaban use.
To analyze the efficacy and safety of activated prothrombin complex concentrates (aPCC) and four-factor prothrombin complex concentrates (4F-PCC) to prevent hematoma expansion in patients taking apixaban or rivaroxaban with intracranial hemorrhage (ICH). In this multicenter, retrospective study, sixty-seven ICH patients who received aPCC or 4F-PCC for known use of apixaban or rivaroxaban between February 2014 and September 2018 were included. The primary outcome was the percentage of patients who achieved excellent/good or poor hemostasis after administration of aPCC or 4F-PCC. Secondary outcomes included hospital mortality, thromboembolic events during admission, and transfusion requirements. Excellent/good hemostasis was achieved in 87% of aPCC patients, 89% of low-dose 4F-PCC [< 30 units per kilogram (kg)], and 89% of high-dose 4F-PCC (>= 30 units per kg). There were no significant differences in excellent/good or poor hemostatic efficacy (p = 0.362). No differences were identified in transfusions 6 h prior (p = 0.087) or 12 h after (p = 0.178) the reversal agent. Mortality occurred in five patients, with no differences among the groups (p = 0.838). There were no inpatient thromboembolic events. Both aPCC and 4F-PCC appear safe and equally associated with hematoma stability in patients taking apixaban or rivaroxaban who present with ICH. Prospective studies are needed to identify a superior reversal agent when comparing andexanet alfa to hospital standard of care (4F-PCC or aPCC) and to further explore the optimal dosing strategy for patients with ICH associated with apixaban or rivaroxaban use.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available